Data WHO/UNICEF & CDC · 21 October 2026 How grades work · Changelog · Corrections

Open Source Medicine Foundation

Bangladesh

Coverage to 2025 · cases to 2025

Vaccination rates and reported vaccine-preventable disease in Bangladesh, with a data-quality grade on every series.

← All countries · South-East Asia

90%
MCV1
2025 · WHO/UNICEF estimate
92%
DTP3
2025 · WHO/UNICEF estimate
92%
HepB3
2025 · WHO/UNICEF estimate
132
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported

Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.

Vaccination coverage

Vaccination coverage by antigen, latest WHO/UNICEF estimate, country-reported figure, trend since 2000 and data-quality grade
VaccineLatest estimateCountry-reportedTrend since 2000Data quality
BCGTuberculosis vaccine at birth94%2025 · WHO/UNICEF estimate94.8%BCG coverage: 2000 to 2025, latest 94% in 2025, lowest 93%, highest 99%.C · weak
DTP1First dose of diphtheria-tetanus-pertussis93%2025 · WHO/UNICEF estimate90.4%DTP1 coverage: 2000 to 2025, latest 93% in 2025, lowest 92%, highest 99%.C · weak
DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme)92%2025 · WHO/UNICEF estimate87.1%DTP3 coverage: 2000 to 2025, latest 92% in 2025, lowest 82%, highest 99%.C · weak
IPV1First dose of inactivated polio vaccine95%2025 · WHO/UNICEF estimate89.3%IPV1 coverage: 2015 to 2025, latest 95% in 2025, lowest 37%, highest 99%.C · weak
IPV completeInactivated polio vaccine, complete primary series—% · Administrative (country-reported)—too few pointsno data
MCV1First dose of measles-containing vaccine90%2025 · WHO/UNICEF estimate92.7%MCV1 coverage: 2000 to 2025, latest 90% in 2025, lowest 74%, highest 97%.C · weak
MCV2Second dose of measles-containing vaccine86%2025 · WHO/UNICEF estimate90.7%MCV2 coverage: 2012 to 2025, latest 86% in 2025, lowest 41%, highest 93%.D · poor
RCV1First dose of rubella-containing vaccine90%2025 · WHO/UNICEF estimate92.7%RCV1 coverage: 2012 to 2025, latest 90% in 2025, lowest 17%, highest 97%.C · weak
HepB3Third dose of hepatitis B vaccine92%2025 · WHO/UNICEF estimate87.1%HepB3 coverage: 2003 to 2025, latest 92% in 2025, lowest 5%, highest 98%.C · weak
HepB birthHepatitis B birth dose within 24 hours—% · Administrative (country-reported)—too few pointsno data
Hib3Third dose of Haemophilus influenzae type b vaccine92%2025 · WHO/UNICEF estimate87.1%Hib3 coverage: 2009 to 2025, latest 92% in 2025, lowest 87%, highest 98%.C · weak
PCV1Pneumococcal conjugate vaccine, first dose90.3%2025 · Administrative (country-reported)90.3%PCV1 coverage: 2015 to 2025, latest 90.26% in 2025, lowest 90.11%, highest 122.29%.D · poor
PCV completePneumococcal conjugate vaccine, final dose of the schedule94%2025 · WHO/UNICEF estimate88.7%PCV complete coverage: 2015 to 2025, latest 94% in 2025, lowest 48%, highest 99%.C · weak
RotaCRotavirus vaccine, complete series—% · Administrative (country-reported)—too few pointsno data
Yellow feverYellow fever vaccine (countries at risk)—% · Administrative (country-reported)—too few pointsno data
MenAMeningococcal A conjugate (meningitis belt)—% · Administrative (country-reported)—too few pointsno data
JEJapanese encephalitis vaccine (countries at risk)—% · Administrative (country-reported)—too few pointsno data
TCVTyphoid conjugate vaccine—% · Administrative (country-reported)—too few pointsno data
PABProtection at birth against neonatal tetanus (maternal tetanus doses)98%2024 · WHO/UNICEF estimate—PAB coverage: 2000 to 2024, latest 98% in 2024, lowest 89%, highest 98%.C · weak
HPV dose 1, girlsHPV programme coverage, first dose, girls3%2025 · WHO/UNICEF estimate—HPV dose 1, girls coverage: 2023 to 2025, latest 3% in 2025, lowest 3%, highest 90%.D · poor
HPV complete, girlsHPV programme coverage, complete series, girls3%2025 · WHO/UNICEF estimate—HPV complete, girls coverage: 2023 to 2025, latest 3% in 2025, lowest 3%, highest 90%.D · poor
HPV dose 1, boysHPV programme coverage, first dose, boys—% · Administrative (country-reported)—too few pointsno data

Reported vaccine-preventable disease

Reported cases and incidence by disease, latest year, trend since 2000 and data-quality grade
DiseaseReported casesIncidence rateTrend since 2000Data quality
Measles all countries · vaccine evidence13220250.8per 1,000,000 total populationMeasles reported cases: 2000 to 2025, latest 132 in 2025, lowest 132, highest 25934.A · strong
Rubella all countries · vaccine evidence11020250.6per 1,000,000 total populationRubella reported cases: 2004 to 2025, latest 110 in 2025, lowest 40, highest 13226.B · good
Congenital rubella syndrome all countries · vaccine evidence520250per 10,000 live birthsCongenital rubella syndrome reported cases: 2013 to 2025, latest 5 in 2025, lowest 5, highest 236.A · strong
Pertussis (whooping cough) all countries · vaccine evidence020250per 1,000,000 total populationPertussis (whooping cough) reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 587.B · good
Diphtheria all countries · vaccine evidence020250per 1,000,000 total populationDiphtheria reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 125.A · strong
Tetanus (total) all countries · vaccine evidence6920250.4per 1,000,000 total populationTetanus (total) reported cases: 2000 to 2025, latest 69 in 2025, lowest 19, highest 1897.A · strong
Neonatal tetanus all countries · vaccine evidence3520250per 1,000 live birthsNeonatal tetanus reported cases: 2000 to 2025, latest 35 in 2025, lowest 19, highest 748.A · strong
Polio (paralytic) all countries · vaccine evidence020210per 1,000,000 <15 populationPolio (paralytic) reported cases: 2000 to 2021, latest 0 in 2021, lowest 0, highest 198.D · poor
Japanese encephalitis all countries · vaccine evidence3720250.2per 1,000,000 total populationJapanese encephalitis reported cases: 2007 to 2025, latest 37 in 2025, lowest 15, highest 1294.A · strong

National schedule (latest WHO listing)

Show the schedule (33 rows)
National immunization schedule
VaccineDoseAgeTarget groupComment
BCGBCG (Baccille Calmette Guérin) vaccine1BGeneral/routine<1 year children
COVID19COVID-19 vaccine1AdultsAll adults, all older adults
COVID19COVID-19 vaccine1Health workersHealth and care workers
COVID19COVID-19 vaccine1Pregnant womenPregnant women
COVID19COVID-19 vaccine1Risk group(s)Adults with chronic conditions, older adults with chronic conditions
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine1W6General/routine<1 year children
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine2W10General/routine<1 year children
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine3W14General/routine<1 year children
HPV2HPV-2 (Human papillomavirus 2-valent) vaccine1Y10HPV for females only10 Years Adolescent Girl
INFLUENZA_ADULTAdult seasonal influenza vaccine1Risk group(s)Other groups
IPV_FRACIPVf (Inactivated polio vaccine fractional dose)1W6General/routineFractional dose
IPV_FRACIPVf (Inactivated polio vaccine fractional dose)3W14General/routineFractional dose
MRMR (Measles and rubella) vaccine1W38General/routine<1 year children; 15-18m children
MRMR (Measles and rubella) vaccine2M15General/routine<1 year children; 15-18m children
OPVOPV (Oral polio vaccine)1W6General/routine<1 year children
OPVOPV (Oral polio vaccine)2W10General/routine<1 year children
OPVOPV (Oral polio vaccine)3W14General/routine<1 year children
PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine1W6General/routine<1 year children
PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine2W10General/routine<1 year children
PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine3W14General/routine<1 year children
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine1Y15-Y49AdultsRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine1Y15-Y49General/routineRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine11st contactPregnant womenRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine2+M1AdultsRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine2+M1General/routineRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine2+M1Pregnant womenRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine3+M6AdultsRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine3+M6General/routineRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine4+Y1AdultsRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine4+Y1General/routineRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine5+Y1AdultsRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine5+Y1General/routineRecommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
VITAMINAVitamin A supplements1M6-M59General/routine6-59 months children

Compare schedules across 31 countries on the schedule hub.

Data and sources

Coverage figures are WHO/UNICEF estimates unless a row says otherwise; reported cases are what national authorities sent to WHO and undercount true infections. Each series carries a data-quality grade that says why.

Cite this page. Bangladesh. Vaccine Data Navigator, Open Source Medicine Foundation. Built 21 October 2026 from WHO/UNICEF (WIISE) exports and CDC SchoolVaxView. https://vaccinedatanavigator.org/disease-risk/countries/bgd.html

Report an error